Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. A double-blind comparison

U. Becker, P. Faurschou, J. Jensen, K. Lindorff, P. B. Pedersen, P. J. Ranløv

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

In a double-blind study 83 patients with duodenal ulcers, initially healed after treatment with either 1 g cimetidine daily or 50 mg trimipramine daily, were allocated by randomization to maintenance treatment with either 400 mg cimetidine daily, 25 mg trimipramine daily, or placebo for 6 months. Monthly clinical interviews were carried out and endoscopy performed whenever the symptoms suggested ulcer relapse. After 6 months the treatment was discontinued, and the patients were observed similarly for another 6-month period. After 6 months of maintenance treatment 88% in the cimetidine group versus 55% in the trimipramine group and 53% in the placebo group remained in symptomatic remission, yielding a significant difference between the cimetidine-treated patients and the two other groups (P < 0.05). After a further 6 months of drug-free follow-up study, the percentages were 48% versus 29% and 29% in the cimetidine, trimipramine, and placebo groups, respectively (P < 0.05). Thus maintenance treatment with trimipramine proved no better than placebo in preventing relapses of duodenal ulcers. Second, maintenance treatment with 400 mg cimetidine daily did prevent ulcer relapse, and third, maintenance treatment with cimetidine for 6 months did not alter the long-term course of the duodenal ulcer disease.

Original languageEnglish
Book seriesScandinavian Journal of Gastroenterology
Volume19
Issue number3
Pages (from-to)405-410
Number of pages6
ISSN0036-5521
Publication statusPublished - 19. Jul 1984

Fingerprint

Cimetidine
Duodenal Ulcer
Placebos
Ulcer
Duodenal Diseases
Random Allocation
Double-Blind Method
Interviews
Pharmaceutical Preparations

Cite this

Becker, U., Faurschou, P., Jensen, J., Lindorff, K., Pedersen, P. B., & Ranløv, P. J. (1984). Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. A double-blind comparison. Scandinavian Journal of Gastroenterology, 19(3), 405-410.
Becker, U. ; Faurschou, P. ; Jensen, J. ; Lindorff, K. ; Pedersen, P. B. ; Ranløv, P. J. / Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. A double-blind comparison. In: Scandinavian Journal of Gastroenterology. 1984 ; Vol. 19, No. 3. pp. 405-410.
@article{1032a261808a4879803322379549036b,
title = "Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. A double-blind comparison",
abstract = "In a double-blind study 83 patients with duodenal ulcers, initially healed after treatment with either 1 g cimetidine daily or 50 mg trimipramine daily, were allocated by randomization to maintenance treatment with either 400 mg cimetidine daily, 25 mg trimipramine daily, or placebo for 6 months. Monthly clinical interviews were carried out and endoscopy performed whenever the symptoms suggested ulcer relapse. After 6 months the treatment was discontinued, and the patients were observed similarly for another 6-month period. After 6 months of maintenance treatment 88{\%} in the cimetidine group versus 55{\%} in the trimipramine group and 53{\%} in the placebo group remained in symptomatic remission, yielding a significant difference between the cimetidine-treated patients and the two other groups (P < 0.05). After a further 6 months of drug-free follow-up study, the percentages were 48{\%} versus 29{\%} and 29{\%} in the cimetidine, trimipramine, and placebo groups, respectively (P < 0.05). Thus maintenance treatment with trimipramine proved no better than placebo in preventing relapses of duodenal ulcers. Second, maintenance treatment with 400 mg cimetidine daily did prevent ulcer relapse, and third, maintenance treatment with cimetidine for 6 months did not alter the long-term course of the duodenal ulcer disease.",
author = "U. Becker and P. Faurschou and J. Jensen and K. Lindorff and Pedersen, {P. B.} and Ranl{\o}v, {P. J.}",
year = "1984",
month = "7",
day = "19",
language = "English",
volume = "19",
pages = "405--410",
journal = "Scandinavian Journal of Gastroenterology. Supplement",
issn = "0085-5928",
publisher = "Taylor & Francis",
number = "3",

}

Becker, U, Faurschou, P, Jensen, J, Lindorff, K, Pedersen, PB & Ranløv, PJ 1984, 'Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. A double-blind comparison', Scandinavian Journal of Gastroenterology, vol. 19, no. 3, pp. 405-410.

Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. A double-blind comparison. / Becker, U.; Faurschou, P.; Jensen, J.; Lindorff, K.; Pedersen, P. B.; Ranløv, P. J.

In: Scandinavian Journal of Gastroenterology, Vol. 19, No. 3, 19.07.1984, p. 405-410.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Relapse prevention of duodenal ulcers with trimipramine, cimetidine, or placebo. A double-blind comparison

AU - Becker, U.

AU - Faurschou, P.

AU - Jensen, J.

AU - Lindorff, K.

AU - Pedersen, P. B.

AU - Ranløv, P. J.

PY - 1984/7/19

Y1 - 1984/7/19

N2 - In a double-blind study 83 patients with duodenal ulcers, initially healed after treatment with either 1 g cimetidine daily or 50 mg trimipramine daily, were allocated by randomization to maintenance treatment with either 400 mg cimetidine daily, 25 mg trimipramine daily, or placebo for 6 months. Monthly clinical interviews were carried out and endoscopy performed whenever the symptoms suggested ulcer relapse. After 6 months the treatment was discontinued, and the patients were observed similarly for another 6-month period. After 6 months of maintenance treatment 88% in the cimetidine group versus 55% in the trimipramine group and 53% in the placebo group remained in symptomatic remission, yielding a significant difference between the cimetidine-treated patients and the two other groups (P < 0.05). After a further 6 months of drug-free follow-up study, the percentages were 48% versus 29% and 29% in the cimetidine, trimipramine, and placebo groups, respectively (P < 0.05). Thus maintenance treatment with trimipramine proved no better than placebo in preventing relapses of duodenal ulcers. Second, maintenance treatment with 400 mg cimetidine daily did prevent ulcer relapse, and third, maintenance treatment with cimetidine for 6 months did not alter the long-term course of the duodenal ulcer disease.

AB - In a double-blind study 83 patients with duodenal ulcers, initially healed after treatment with either 1 g cimetidine daily or 50 mg trimipramine daily, were allocated by randomization to maintenance treatment with either 400 mg cimetidine daily, 25 mg trimipramine daily, or placebo for 6 months. Monthly clinical interviews were carried out and endoscopy performed whenever the symptoms suggested ulcer relapse. After 6 months the treatment was discontinued, and the patients were observed similarly for another 6-month period. After 6 months of maintenance treatment 88% in the cimetidine group versus 55% in the trimipramine group and 53% in the placebo group remained in symptomatic remission, yielding a significant difference between the cimetidine-treated patients and the two other groups (P < 0.05). After a further 6 months of drug-free follow-up study, the percentages were 48% versus 29% and 29% in the cimetidine, trimipramine, and placebo groups, respectively (P < 0.05). Thus maintenance treatment with trimipramine proved no better than placebo in preventing relapses of duodenal ulcers. Second, maintenance treatment with 400 mg cimetidine daily did prevent ulcer relapse, and third, maintenance treatment with cimetidine for 6 months did not alter the long-term course of the duodenal ulcer disease.

UR - http://www.scopus.com/inward/record.url?scp=0021255803&partnerID=8YFLogxK

M3 - Journal article

VL - 19

SP - 405

EP - 410

JO - Scandinavian Journal of Gastroenterology. Supplement

JF - Scandinavian Journal of Gastroenterology. Supplement

SN - 0085-5928

IS - 3

ER -